Darwin, development, Drosophila, and disease^†

• Pages: 1-3
• First Published: 23 December 2009

Lipidomic dissection of nonalcoholic steatohepatitis: Moving beyond foie gras to fat traffic^†‡

• Pages: 4-7
• First Published: 23 December 2009

Natural killer group 2 member D, its ligands, and liver disease: Good or bad?^†‡

• Pages: 8-11
• First Published: 23 December 2009

Multifaceted perspective of the waiting list for liver transplantation: The value of pharmacokinetic models^†‡

• Pages: 12-15
• First Published: 23 December 2009

Fluorescent in situ hybridization testing in primary sclerosing cholangitis: Useful testing or a random chance result?^†‡

• Pages: 16-19
• First Published: 23 December 2009

Hepatocytes from induced pluripotent stem cells: A giant leap forward for hepatology^†‡

• Pages: 20-22
• First Published: 23 December 2009

Liver stiffness identifies two different patterns of fibrosis progression in patients with hepatitis C virus recurrence after liver transplantation^†

• Pages: 23-34
• First Published: 23 December 2009

Impaired expression and function of toll-like receptor 7 in hepatitis C virus infection in human hepatoma cells^†

• Pages: 35-42
• First Published: 23 December 2009

Apolipoprotein E interacts with hepatitis C virus nonstructural protein 5A and determines assembly of infectious particles^†

• Pages: 43-53
• First Published: 23 December 2009

Protective effect of human leukocyte antigen B27 in hepatitis C virus infection requires the presence of a genotype-specific immunodominant CD8+ T-cell epitope^†

• Pages: 54-62
• First Published: 23 December 2009

Control of hepatitis B virus replication by innate response of HepaRG cells^†

• Pages: 63-72
• First Published: 23 December 2009

Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues^†

• Pages: 73-80
• First Published: 23 December 2009

Interleukin-17–producing CD4⁺ T cells increase with severity of liver damage in patients with chronic hepatitis B^†

• Pages: 81-91
• First Published: 23 December 2009

Major histocompatibility complex class I–related chains A and B (MIC A/B): A novel role in nonalcoholic steatohepatitis^†

• Pages: 92-102
• First Published: 23 December 2009

Increased tumor necrosis factor α–converting enzyme activity induces insulin resistance and hepatosteatosis in mice^†

• Pages: 103-110
• First Published: 23 December 2009

Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease^†‡

• Pages: 111-120
• First Published: 23 December 2009

Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis^†

• Pages: 121-129
• First Published: 23 December 2009

Kupffer cell and interleukin-12–dependent loss of natural killer T cells in hepatosteatosis^†

• Pages: 130-141
• First Published: 23 December 2009

Epigenetic silence of ankyrin-repeat–containing, SH3-domain–containing, and proline-rich-region– containing protein 1 (ASPP1) and ASPP2 genes promotes tumor growth in hepatitis B virus–positive hepatocellular carcinoma^†

• Pages: 142-153
• First Published: 23 December 2009

Activated monocytes in peritumoral stroma of hepatocellular carcinoma promote expansion of memory T helper 17 cells^†

• Pages: 154-164
• First Published: 23 December 2009

Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: A cost-benefit analysis while awaiting data on sorafenib safety^†

• Pages: 165-173
• First Published: 23 December 2009

Long-term outcomes of positive fluorescence in situ hybridization tests in primary sclerosing cholangitis^†

• Pages: 174-180
• First Published: 23 December 2009

Mouse organic solute transporter α deficiency enhances renal excretion of bile acids and attenuates cholestasis^†

• Pages: 181-190
• First Published: 23 December 2009

Liver injury in acute fatty liver of pregnancy: Possible link to placental mitochondrial dysfunction and oxidative stress^†

• Pages: 191-200
• First Published: 23 December 2009

Increased caffeine consumption is associated with reduced hepatic fibrosis^†

• Pages: 201-209
• First Published: 23 December 2009

Acute portal vein thrombosis unrelated to cirrhosis: A prospective multicenter follow-up study^†

• Pages: 210-218
• First Published: 23 December 2009

Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome^†

• Pages: 219-226
• First Published: 23 December 2009

Acetaminophen dosing of humans results in blood transcriptome and metabolome changes consistent with impaired oxidative phosphorylation^†

• Pages: 227-236
• First Published: 23 December 2009

Role of acid sphingomyelinase of Kupffer cells in cholestatic liver injury in mice^†

• Pages: 237-245
• First Published: 23 December 2009

Novel mechanisms of protection against acetaminophen hepatotoxicity in mice by glutathione and N-acetylcysteine^†

• Pages: 246-254
• First Published: 23 December 2009

Inhibition of poly adenosine diphosphate-ribose polymerase decreases hepatocellular carcinoma growth by modulation of tumor-related gene expression^†

• Pages: 255-266
• First Published: 23 December 2009

Bone marrow transplantation demonstrates medullar origin of CD34⁺ fibrocytes and ameliorates hepatic fibrosis in Abcb4^−/− mice^†

• Pages: 267-276
• First Published: 23 December 2009

Mechanisms for increased expression of cholesterol 7α-hydroxylase (Cyp7a1) in lactating rats^†

• Pages: 277-285
• First Published: 23 December 2009

Folding defects in P-type ATP 8B1 associated with hereditary cholestasis are ameliorated by 4-phenylbutyrate^†

• Pages: 286-296
• First Published: 23 December 2009

Highly efficient generation of human hepatocyte–like cells from induced pluripotent stem cells^†

• Pages: 297-305
• First Published: 23 December 2009

The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension: Update 2009^†

• Page: 306
• First Published: 23 December 2009

Alcoholic liver disease^†

• Pages: 307-328
• First Published: 23 December 2009

Generation of functional human hepatic endoderm from human induced pluripotent stem cells^†

• Pages: 329-335
• First Published: 23 December 2009

IκB kinase ε: A potential therapeutic target for obesity (and nonalcoholic fatty liver disease)?^†

• Pages: 336-338
• First Published: 23 December 2009

N-acetylcysteine on its way to a broader application in patients with acute liver failure^†

• Pages: 338-340
• First Published: 23 December 2009

A case of fulminant hepatic failure in pregnancy^†

• Pages: 341-342
• First Published: 23 December 2009

Hepatitis C virus infection, lipids, and coronary heart disease: A Pandora's box^†

• Page: 343
• First Published: 23 December 2009

Reply:^†

• Pages: 343-344
• First Published: 23 December 2009

New translational research on novel drugs for hepatitis C virus 1b infection by using a replicon system and human induced pluripotent stem cells^†

• Pages: 344-345
• First Published: 23 December 2009

Reply:^†

• Page: 345
• First Published: 23 December 2009

Supporting evidence for natural killer T cell accumulation in progressive nonalcoholic fatty liver disease?^†

• Pages: 345-346
• First Published: 23 December 2009

Reply:^†

• Page: 346
• First Published: 23 December 2009

Minocycline sensitizes rodent and human liver mitochondria to the permeability transition: Implications for toxicity in liver transplantation^†

• Pages: 347-348
• First Published: 23 December 2009

Minocycline protects against the mitochondria permeability transition after both warm and cold ischemia-reperfusion^†

• Pages: 349-350
• First Published: 23 December 2009

Diagnostic criteria for autoimmune hepatitis: What is the gold standard?^†

• Pages: 350-351
• First Published: 23 December 2009

Reply:^†

• Page: 351
• First Published: 23 December 2009

An identification of the novel combination therapy for hepatitis C virus 1b infection by using a replicon system and human induced pluripotent stem cells^†

• Pages: 351-352
• First Published: 23 December 2009

Statins and hepatitis C virus: Friend or foe?^†

• Page: 352
• First Published: 23 December 2009

Human immunodeficiency virus and hepatitis C infections induce distinct immunologic imprints in peripheral mononuclear cells^†

• Page: 353
• First Published: 23 December 2009

Protection of mitochondrial genome integrity: A new stem cell property?^†

• Page: 354
• First Published: 23 December 2009

Limitations of the algorithm for the SAFE biopsy: A noninvasive fibrosis measure in chronic hepatitis C^†

• Pages: 354-355
• First Published: 23 December 2009

Is it difficult to obtain an optimal liver biopsy specimen?^†

• Pages: 355-356
• First Published: 23 December 2009

The cirrhosis risk score predicts liver fibrosis progression in patients with initially mild chronic hepatitis C^†

• Pages: 356-357
• First Published: 23 December 2009

• Page: 358
• First Published: 23 December 2009

• Page: 358
• First Published: 23 December 2009